Abstract: Featured are methods, devices, and kits for detecting gene expression in a patient with a cancer and methods for determining responsiveness of a patient with a cancer to a treatment, such as treatment with ixabepilone or a pharmaceutically acceptable salt thereof. Also disclosed are methods of treating a patient with a cancer by administering a treatment, e.g., treatment with ixabepilone or a pharmaceutically acceptable salt thereof, in particular when the patient is determined to be responsive to the treatment based on the expression of the biomarkers described herein.

Abstract: The present invention features methods, devices, and kits for detecting gene expression in a patient with a cancer or determining responsive of a patient with a cancer to a treatment, such as treatment with dovitinib or a pharmaceutically acceptable salt thereof. The invention further includes methods of treating a patient with a cancer by administering a treatment, e.g., treatment with dovitinib or a pharmaceutically acceptable salt thereof, in particular when the patient is determined to be responsive to the treatment based on the expression of the biomarkers described herein.

Abstract: The present invention features methods, devices, and kits for detecting expression in a patient having cancer or determining responsive of a patient having cancer to a treatment, such as irofulven. The invention further includes methods of treating a patient having cancer by administering, e.g., irofulven.

Abstract: The present invention features methods, devices, and kits for detecting gene expression in a patient with a cancer or determining responsive of a patient with a cancer to a treatment, such as treatment with 2X-121 or a pharmaceutically acceptable salt thereof. The invention further includes methods of treating a patient with a cancer by administering a treatment, e.g., treatment with 2X-121 or a pharmaceutically acceptable salt thereof, in particular when the patient is determined to be responsive to the treatment based on the expression of the biomarkers described herein.

Abstract: The present invention features methods, devices, and kits for detecting a level of one or more biomarkers in a patient having cancer or determining the responsiveness of a patient having cancer to a treatment, such as treatment with a secretory phospholipase A2 (sPLA2) hydrolysable, cisplatin-containing liposome. The invention further includes methods of treating a patient having cancer by administering, e.g., the liposome.

Abstract: The present invention features methods, devices, and kits for detecting a level of one or more biomarkers in a patient with cancer or determining the responsiveness of a patient with cancer to a treatment, such as treatment with an anthracycline. The invention further includes methods of treating a patient with cancer by administering, e.g., the anthracycline.

Abstract: The present invention features methods, devices, and kits for detecting gene expression in a patient with a cancer or determining responsive of a patient with a cancer to a treatment, such as treatment with dovitinib or a pharmaceutically acceptable salt thereof. The invention further includes methods of treating a patient with a cancer by administering a treatment, e.g., treatment with dovitinib or a pharmaceutically acceptable salt thereof, in particular when the patient is determined to be responsive to the treatment based on the expression of the biomarkers described herein.

Abstract: The present invention features methods, devices, and kits for detecting expression in a patient having cancer or determining responsive of a patient having cancer to a treatment, such as irofulven. The invention further includes methods of treating a patient having cancer by administering, e.g., irofulven.

Abstract: The present invention provides drug response predictors and biomarkers useful for assessing the responsiveness of a subject to treatment with one or more target drugs of interest, such as 5-fluorouracil (5-FU), irinotecan, and/or oxaliplatin. In particular, the invention provides methods useful in determining whether a subject is sensitive or resistant to a target drug by, e.g., measuring the expression level of one or more biomarkers of sensitivity and/or resistance to the drug in a biological sample obtained from the subject. The invention further features devices and kits for assessing target drug responsiveness in a subject, for example, by determining the expression level of such biomarkers.

Abstract: The present invention features methods, devices, and kits for predicting the sensitivity of a patient to a compound or medical treatment, such as fulvestrant.

Abstract: Featured are methods of treating a patient with cancer by administering, e.g., a secretory phospholipase A2 (sPLA2) hydrolysable, cisplatin-containing liposome composition (e.g., LiPlaCis). The patient may be assessed for their responsiveness to the liposomal therapy prior to treatment using the methods, devices, and kits also described herein for detecting a level of one or more biomarkers in a sample from the patient with cancer.

Abstract: The present invention features methods, devices, and kits for detecting a level of one or more biomarkers in a patient with cancer or determining the responsiveness of a patient with cancer to a treatment, such as treatment with an anthracycline. The invention further includes methods of treating a patient with cancer by administering, e.g., the anthracycline.

Abstract: The present invention features methods, devices, and kits for detecting a level of one or more biomarkers in a patient having cancer or determining the responsiveness of a patient having cancer to a treatment, such as treatment with a secretory phospholipase A2 (sPLA2) hydrolysable, cisplatin-containing liposome. The invention further includes methods of treating a patient having cancer by administering, e.g., the liposome.

Abstract: The present invention features methods, devices, and kits for detecting expression in a patient having cancer or determining responsive of a patient having cancer to a treatment, such as irofulven. The invention further includes methods of treating a patient having cancer by administering, e.g., irofulven.

Abstract: The present invention features methods, devices, and kits for detecting gene expression in a patient having cancer or determining responsive of a patient having cancer to a treatment, such as APO010. The invention further includes methods of treating a patient having cancer by administering, e.g., APO010.

Abstract: The present invention provides drug response predictors and biomarkers useful for assessing the responsiveness of a subject to treatment with one or more target drugs of interest, such as 5-fluorouracil (5-FU), irinotecan, and/or oxaliplatin. In particular, the invention provides methods useful in determining whether a subject is sensitive or resistant to a target drug by, e.g., measuring the expression level of one or more biomarkers of sensitivity and/or resistance to the drug in a biological sample obtained from the subject. The invention further features devices and kits for assessing target drug responsiveness in a subject, for example, by determining the expression level of such biomarkers.

Abstract: The present invention features methods, devices, and kits for detecting expression in a patient having cancer or determining responsive of a patient having cancer to a treatment, such as irofulven. The invention further includes methods of treating a patient having cancer by administering, e.g., irofulven.

Abstract: The present invention features methods, devices, and kits for predicting the sensitivity of a patient to a compound or medical treatment. The invention also features methods for identifying biomarkers, the expression of which correlates to treatment sensitivity or resistance within a patient population or subpopulation.

Abstract: The invention features methods for predicting responsiveness to chemotherapy drug(s) in cancer patients (e.g., patients with lymphoma (e.g, patients with DLBCL)), by, e.g., determining a level of expression of one or more biomarkers in a biological sample obtained from the patient.

Abstract: The present invention features methods, devices, and kits for predicting the sensitivity of a patient to a compound or medical treatment, such as fulvestrant.